Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1595205 | 1.00 | AAK1 (0.44) | AAK1RAB9ANPC1EPHX2KMT2A | |
| SCHEMBL1594865 | 0.91 | KDM4E (0.46) | RAB9ANPC1KMT2AMEN1HPGD | |
| SCHEMBL1595876 | 0.91 | KDM4E (0.46) | RAB9ANPC1KMT2AMEN1HPGD | |
| SCHEMBL1595365 | 0.89 | RAB9A (0.43) | AAK1RAB9ANPC1EPHX2KMT2A | |
| SCHEMBL1594478 | 0.89 | RAB9A (0.43) | AAK1RAB9ANPC1EPHX2KMT2A | |
| SCHEMBL1595898 | 0.89 | EPHX2 (0.43) | AAK1RAB9ANPC1EPHX2P2RX7 | |
| SCHEMBL1595001 | 0.89 | EPHX2 (0.43) | AAK1RAB9ANPC1EPHX2P2RX7 | |
| SCHEMBL178040 | 0.88 | RAB9A (0.46) | AAK1RAB9ANPC1EPHX2KMT2A | |
| SCHEMBL177958 | 0.88 | RAB9A (0.46) | AAK1RAB9ANPC1EPHX2KMT2A | |
| SCHEMBL7897209 | 0.88 | AAK1 (0.42) | AAK1RAB9ANPC1EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | claimed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | claimed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | claimed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | claimed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | claimed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | claimed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | claimed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268861-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2243772-B1 | Novel P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7919503-B2 | P2X7R antagonists and their use | AFFECTIS PHARMACEUTICALS AG (DE) | 2011-04-05 | — | — | US | disclosed |
| EP-2243772-A1 | Novel P2X7R antagonists and their use | Affectis Pharmaceuticals AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010118921-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | AFFECTIS PHARMACEUTICALS AG (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212992-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | AAK1 1223/4885RAB9A 3807/4885NPC1 1162/4885 |
| US-20100267762-A1 | NOVEL P2X7R ANTAGONISTS AND THEIR USE | P2RX3, P2RX2, P2RX1 | AAK1 1223/4885RAB9A 3807/4885NPC1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.